Status:
RECRUITING
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.
Detailed Description
The primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of Small/Middle tier cities and County hospitals, after sta...
Eligibility Criteria
Inclusion
- Age ≥18 years, at the time of signing the informed consent.
- ECOG performance status 0-2.
- Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.
Exclusion
- Be participating in other intervention clinical trials.
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
- Previous enrolment in the other QIP study.
Key Trial Info
Start Date :
November 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 28 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06494241
Start Date
November 22 2024
End Date
November 28 2027
Last Update
December 11 2025
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anning, China
2
Research Site
Anqing, China
3
Research Site
Changzhi, China
4
Research Site
Daqing, China